Pernille B. Laerkegaard汉森

As the 执行董事 and Head of Renal Bioscience, 心血管，肾脏和代谢 (CVRM) and a member of the CVRM Review Board, I lead 澳门在线赌城娱乐’s early research strategy on 肾脏疾病 and work closely with our commercial and late-stage development teams.

通过领导澳门第一赌城在线娱乐的早期肾脏研究策略, I help to ensure that we use patient-first thinking and build our scientific understanding of these diseases to identify and validate treatment targets that address unmet clinical needs. I am accountable for delivering new drug targets to the renal portfolio and work with my team to identify and validate novel targets and pathways of interest. My responsibilities include integrating the latest technologies – including 人工智能 (AI)和 数字医疗 解决方案-纳入澳门第一赌城在线娱乐的研究, 并提出潜在的药物靶点供审查, to ensure we are always focused on projects with the greatest potential to improve the lives of patients.

My academic career began with my PhD at the University of Southern Denmark, focusing on vascular resistance in renal blood vessels using 在体外 技术. 在接下来的15年里, I undertook postdoctoral research at the 美国国立卫生研究院 before returning to the University of Southern Denmark where I taught and came to lead a research group. I have acquired extensive experience studying the kidney using 在体外, 在活的有机体内 and translational approaches and since joining 澳门在线赌城娱乐, 我帮助搭建了学术和行业兴趣的桥梁. This has led to collaborations with the Karolinska Institutet and Harvard Medical School, 等. I am also leading an partnership with Benevolent AI to integrate its AI capabilities with 澳门在线赌城娱乐’s scientific excellence to deliver novel targets for chronic kidney disease (CKD).

除了我在澳门在线赌城娱乐的角色, I hold academic positions as 南丹麦大学教授 and 哥德堡 University. My scientific interests are kidney pathophysiology, kidney function and blood pressure regulation. The evidence from our research formed the basis for translational research that is informing novel advances in understanding kidney disease.